New medical reform brings new business opportunities to the medical industry to become "Xiangxiang"

On November 17, Royal Philips Electronics of the Netherlands announced its largest investment plan in China's medical sector, with an investment of US$54 million to build an imaging base in the Suzhou Industrial Park. Philips signed a signing ceremony with the Suzhou Municipal Government on the 17th. Luo Siqi, executive vice president of Philips and chief executive of the Healthcare Business Unit, who attended the signing ceremony, told reporters that “the project will be one of the largest medical imaging production bases in the world.”

Foreign actively participate in China's medical reform <br> <br> Philips Medical Imaging Chinese base in a total area of 62,000 square meters, plans to invest a total of $ 54 million over the next five years, the project is expected to be completed in mid-2012. The base will integrate R&D, manufacturing, assembly and procurement facilities, as well as a global leading R&D center.

GeneSaragness, executive vice president of Philips Electronics and CEO of the Medical Imaging Systems of the Healthcare Division, said in an interview that China's medical system reform has promoted the establishment of the Suzhou base.

Under the influence of the global financial crisis, the international mainstream medical device market has tended to shrink, and China's new medical reform policy has enabled foreign investors to see opportunities in the Chinese market. Among them, the medical reform will be 850 billion yuan, and a large part will be used for the purchase of equipment. According to estimates by multinational corporations, central and local governments will invest more than 100 billion yuan in medical device procurement in 2009.

With the rapid development of the healthcare industry and the growing desire for people to improve their quality of life, many domestic hospitals do not need to update their medical equipment to improve the quality of patient care and improve the operational efficiency of medical institutions. Luo Siqi mentioned in his speech that "China's medical equipment market is growing at a rate of 13.9%. China is one of our very important emerging markets. In the 'BRICs', China is especially important for Philips."

China is Philips' third largest market in the world, and Philips' business grew at double-digit rates last year. Luo Siqi added that "this year's high-end CT sales in China have exceeded the United States."

In the field of medical equipment, Philips has accelerated its presence in China. Philips has previously had a joint venture with Neusoft and acquired Shenzhen Jinkewei, the second largest patient monitoring equipment manufacturer in China. Luo Siqi said, "With the medical imaging China base, Philips Medical will cover a more complete product line in China, which can meet the global market related needs including domestic customers."

Developing low-end products is encouraged

Yao Xinzhong, deputy director of the Jiangsu Food and Drug Administration, who attended the signing ceremony, said that at the beginning of this year, the new medical reform plan proposed a large investment plan of 850 billion yuan for medical insurance, primary medical service system, and equalization of public services. Businesses offer great business opportunities. The new medical reform program guides enterprises to develop the low-end market and promote the sustainable development of the medical industry .

The products produced by Philips Medical Imaging Suzhou Base are mainly economical equipment, which is targeted at the low-end market. This is in line with the reform of the medical system initiated by China. The base will produce 64 rows of CT (computed tomography scanner) and 1.5 MR (magnetic resonance imaging system), both of which are the mainstream imaging equipment used by most provincial and municipal hospitals in China. X-ray equipment will also be produced to meet the market demand of medium-sized hospitals.

The pharmaceutical industry has become the highlight local economic development <br> <br> new medicine industry has become Jiangsu Province to speed up transformation and upgrading process the highlight of Jiangsu has entered a new priority to the development of the pharmaceutical industry, accelerate the development of the golden period. Yao Xinzhong revealed that “Jiangsu strives to double the output value of this new industry within three years and cultivate a large number of local professionals in the process to serve the Chinese medical reform process.”

Since 2009, despite the international financial crisis, the scale of investment in the pharmaceutical industry in Suzhou has shown a rapid expansion, and its growth rate is far ahead of other industries. At present, Suzhou has gathered more than 3,000 professional biotechnology companies and more than 500 pharmaceutical manufacturers. Among them, 9 global 500 compulsory pharmaceutical companies such as Pfizer, Glaxo, Novartis and Lilly have invested in Suzhou. . More and more bio-pharmaceutical companies set up R&D centers in Suzhou, making Suzhou, which is on the road to transformation and upgrading, also achieving a transition from a “medical market” to a “medical strong city”.

It is understood that Suzhou City has clearly proposed that medicine and biotechnology as one of the emerging strategic industries that will be cultivated in the new era, as one of the “four major industrial leap-forward development projects” in Suzhou, and formulated the “Suzhou Pharmaceutical and Biotechnology”. Industry Improvement and Development Plan.

Ma Minglong, secretary of the working committee of Suzhou Industrial Park, told the reporter: "The total industrial output value of Suzhou has now ranked second in the country, but we will focus on cultivating some emerging strategic industries, such as biomedical industry. This industry is the fastest growing high technology in the world. One of the content and high value-added industries implies huge economic and social benefits. In the future, Suzhou will further strengthen fiscal and taxation financial guidance and support, introduce and cultivate more biomedical talents, and strive to build Suzhou into the Yangtze River Delta and even the national pharmaceutical and biotechnology. One of the innovative cities."

60*90 Under Pads

Medline Underpads,Covidien Underpads,Washable Underpads,Bed Underpads Incontinence

Shandong Kangshun Daily Products Co., Ltd , https://www.centurybenifit.com